OncoHost Launches PROphet® NSCLC Test in the United States

Original source here.

On February 1, 2023, OncoHost, a precision diagnostics company centered on predictive biomarker development for improved patient care, announced the official launch of its PROphet® non-small cell lung cancer (NSCLC) Test in the United States. OncoHost’s first test, PROphet® NSCLC, guides first-line treatment decisions for advanced unresectable NSCLC patients. The PROphet® NSCLC Test provides clinicians with actionable clinical insights into optimal first-line therapeutic choices, and a better understanding of their patients’ personalized cancer dynamics. Requiring just one pre-treatment blood test, PROphet® scans approximately 7,000 proteins in a patient’s blood plasma and delivers a report that predicts the patient’s clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment plans versus clinical benefit from immunotherapy plus chemotherapy.

The PROphet Test is intended for use by the physician as an aid for managing unresectable stage III and IV non-small cell lung cancer (NSCLC) patients treated with first-line anti-PD-1/PD-L1-based therapy as a single agent or in combination with chemotherapy. The test also gives treatment considerations that include clinical trial options.  

“After years of research, development, and determination, we are proud to be launching our PROphet® NSCLC test in the United States,” said Ofer Sharon, MD, CEO of OncoHost. “While driver mutation detection is essential in determining effective treatment, approximately 85% of all patients diagnosed with NSCLC do not have any detectable driver mutations. In these cases, the PROphet® NSCLC Test, when combined with PD-L1 results, will serve an invaluable purpose in predicting the best treatment plan for each individual patient. We hope to create a shift in the industry and improve the lives of those fighting this disease.”

The PROphet® algorithm is trained on OncoHost’s large-scale clinical trial, PROPHETIC. To date, the trial has over 1,500 patients recruited across 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field. The PROphet® NSCLC Test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.

“We are thrilled to be launching the PROphet® NSCLC test, offering a predictive biomarker to guide treatment planning for this large subset of patients,” said Chris Dingman, OncoHost CCO. “Access to our test will have a significant impact on patient care and treatment protocols. The PROphet® Report will guide physicians’ treatment decisions by offering personalized insights on the predicted clinical benefit of immunotherapy. Combining these findings with the patient’s PD-L1 level will allow physicians to offer the most effective plan and avoid unnecessary treatments.”

More Detail

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in NSCLC patients. The model is based on proteomic profiling of pre-treatment blood samples, combined with machine learning analysis that accurately predicts clinical benefit probability at twelve months, outperforming the predictive capabilities of the existing PD-L1 biomarker.

Recent clinical trial results from OncoHost were presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. OncoHost also gave an oral presentation at the recent Precision Medicine World Conference (PMWC 2023) (January 25-27) in Silicon Valley in California.

Currently, clinical benefit prediction of ICI therapy and selecting an effective and safe treatment modality (i.e., immunotherapy alone vs. combination of immunotherapy with chemotherapy) relies on PD-L1 expression levels. However, the available assays are only moderately predictive. In addition, the clinical benefit of immunotherapy-based strategies is still limited to a minority of patients, reflecting the need to identify predictive biomarkers of clinical benefit and ultimately improve patient selection for truly personalized treatment plans.

Michal Harel, Ph.D., Director of Science and Innovation at OncoHost noted, “Our proprietary machine learning and proteomics-based platform, PROphet®, provides two clinical utilities; first, it can successfully predict clinical benefit at twelve months; second, the model, combined with PD-L1 testing, provides a decision-making tool for physicians on whether to administer immunotherapy alone or in combination with chemotherapy for their patients, with a significant effect on overall survival.”

To order the PROphet® NSCLC test, any physician can visit the OncoHost website at www.oncohost.com and complete a Test Requisition Form.

About OncoHost

OncoHost is a precision diagnostics company headquartered in Binyamina, Israel, and Cary, North Carolina, centered on predictive biomarker development for improved patient care. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic analysis tool whose initial offering in NSCLC uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC Test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts, and supported by a large-scale prospective clinical trial with over 40 sites and 1500 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, and Facebook.